Tarsus Pharmaceuticals (TARS) EBIT Margin (2021 - 2026)

Tarsus Pharmaceuticals' EBIT Margin history runs 6 years deep, the most recent figure standing at 3.78% for Q1 2026.

• In Q1 2026, EBIT Margin rose 2977.0% year-over-year to 3.78%; the TTM figure through Mar 2026 stood at 9.5% (up 3722.0% YoY), while the FY2025 annual figure was 15.72%, up 5018.0% from the prior year.
• EBIT Margin was 3.78% for Q1 2026 at Tarsus Pharmaceuticals, up from 5.26% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 3.78% in Q1 2026 to a low of 3621.71% in Q1 2022.
• Historically, EBIT Margin has averaged 514.4% across 5 years, with a median of 52.29% in 2024.
• Biggest YoY gain for EBIT Margin was 412395 bps in 2022; the steepest drop was 365375 bps in 2022.
• A 5-year view of EBIT Margin shows it stood at 150.61% in 2022, then tumbled by 126 bps to 339.94% in 2023, then surged by 89 bps to 36.77% in 2024, then jumped by 86 bps to 5.26% in 2025, then grew by 28 bps to 3.78% in 2026.
• The last three EBIT Margin figures came in at 3.78% (Q1 2026), 5.26% (Q4 2025), and 12.24% (Q3 2025), per Business Quant data.